What is the recommended management of measles in an adult patient?

Management of Measles in Adults

Measles management in adults is primarily supportive, focusing on symptom relief, monitoring for complications, and preventing secondary bacterial infections, with no specific antiviral therapy currently recommended for routine use. 1

Immediate Supportive Care

The cornerstone of measles management consists of:

• Hydration and fever management – Maintain adequate fluid intake and use antipyretics for fever control 1, 2
• Nutritional support – Monitor nutritional status and provide adequate caloric intake, particularly in hospitalized patients 3, 4
• Rest and isolation – Patients remain infectious from 4 days before rash onset through 4 days after, requiring strict airborne precautions 5

Vitamin A Supplementation

While vitamin A is strongly recommended for children with measles, evidence for routine use in adults is limited. However, consider supplementation in specific circumstances:

• Immunocompromised adults or those with malnutrition may benefit from vitamin A supplementation, though adult-specific dosing guidelines are not well-established 3, 2
• The pediatric evidence demonstrates 64% reduction in overall mortality and 67% reduction in pneumonia-specific mortality with two-dose regimens 3
• Do not withhold vitamin A in malnourished adults; undernutrition is an indication for aggressive supportive therapy, not a contraindication 3

Management of Complications

Bacterial superinfections are common and require prompt antibiotic therapy:

• Pneumonia – Occurs in up to 39% of hospitalized adults; treat with appropriate antibiotics based on suspected or confirmed pathogens 4, 6
• Otitis media – Administer suitable antibiotic therapy per standard protocols 3
• Secondary bacterial infections – Suspected in the majority of severe cases requiring ICU admission; obtain cultures and initiate empiric antibiotics when clinically indicated 4

Respiratory complications:

• Acute respiratory distress syndrome (ARDS) – Developed in 9 of 11 mechanically ventilated adults in one cohort; requires intensive care with lung-protective ventilation strategies 4
• Mechanical ventilation – May be necessary for severe pneumonitis; be vigilant for air leak complications (pneumothorax, pneumomediastinum) which occurred in 44% of ARDS cases 4

Neurological complications:

• Encephalomyelitis – Uncommon but serious; requires supportive care and monitoring for sequelae including paraparesis and bladder dysfunction 1, 4
• Acute disseminated encephalomyelitis – Can occur during or shortly after acute illness 1

Laboratory Monitoring

Expect and monitor for multi-organ involvement:

• Hepatic transaminases – Elevated (>5× upper limit of normal) in 28-39% of hospitalized adults 6
• Lactate dehydrogenase – Elevated (>5× upper limit of normal) in 28% of cases 6
• Serum calcium – Hypocalcemia (≤2.0 mmol/L) develops in 54% of hospitalized adults 6
• Creatine kinase – Elevated (>5× upper limit of normal) in 31% of patients 6

High-Risk Populations Requiring Aggressive Management

Immunocompromised patients:

• All five deaths in one ICU cohort occurred among severely immunocompromised patients 4
• Immune globulin (IG) 0.5 mL/kg IM (maximum 15 mL) should be administered if exposed, regardless of vaccination status 7
• Measles vaccine is contraindicated in severely immunocompromised individuals 8, 7

Pregnant women:

• Five pregnant women in one series had variable outcomes, including one requiring emergent cesarean delivery for fetal growth restriction 4
• Measles vaccine is contraindicated during pregnancy 8
• Post-exposure IG 0.25 mL/kg IM (maximum 15 mL) within 6 days of exposure is the recommended prophylaxis 8

Unvaccinated adults:

• Higher risk for severe disease requiring ICU admission (27% in one series) and prolonged hospitalization (mean 6.8 days, up to 13.4 days for ICU patients) 6
• Post-exposure MMR vaccination within 72 hours can prevent or modify disease if not contraindicated 8, 5

Post-Exposure Prophylaxis for Contacts

For exposed adults without evidence of immunity:

• MMR vaccine within 72 hours of exposure is the preferred intervention when not contraindicated 8, 5, 3
• Immune globulin 0.25 mL/kg IM (maximum 15 mL) within 6 days when vaccine is contraindicated 8, 3
• Healthcare personnel without immunity should be excluded from work days 5-21 after exposure, even if they receive post-exposure IG 5

Infection Control in Healthcare Settings

Strict airborne precautions are mandatory:

• N-95 respirators for all staff entering patient rooms, regardless of immunity status 5, 2
• Airborne infection isolation room (negative pressure) immediately upon suspicion 5
• Exclude infected healthcare workers from patient contact until ≥4 days after rash onset 5

Evidence of Immunity in Adults

Adults are considered immune if they have:

• Born before 1957 (though this does not apply to healthcare personnel) 9, 10
• Documentation of 2 doses of MMR vaccine at least 28 days apart 9
• Laboratory evidence of immunity (serologic confirmation) 9, 10
• Provider-diagnosed measles with laboratory confirmation 9

Common Pitfalls to Avoid

• Do not delay antibiotic therapy when bacterial superinfection is suspected; documented bacterial infection occurred in only 29% of cases where it was clinically suspected, but empiric treatment is often necessary 4
• Do not assume vaccinated adults are protected; breakthrough cases occurred in 44% of secondary cases in one recent outbreak, though symptoms were milder 11
• Do not rely solely on nasopharyngeal swabs for diagnosis in vaccinated individuals; urine RT-PCR may be positive when nasopharyngeal specimens are negative 11
• Do not underestimate severity in young adults; the mean age of ICU admissions was 29.2 years, and adults born after 1957 may have waning vaccine-derived immunity 4, 12